North America Anti diabetic Biosimilars Market: By Drug Class -IV Inhibitors, ?-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others), By Disease Type, By Distribution Channel and Country
North America Anti diabetic Biosimilars Market size was valued at US$ 9,690.2 million in 2024 and is expected to reach US$ 84,250.9 million by 2031, growing at a significant CAGR of 36.2% from 2025-2031. Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules.
Increase in the prevalence of diabetic patients. Patent expiries block buster drugs and promising product pipeline. Rise in R&D activities for the innovation of Insulin biosimilars Restraints: High cost of R&D activities. Stringent regulatory policies. Complexity in development of biosimilars
|
Report Benchmarks |
Details |
|
Market Size in 2024 |
US$ 9,690.2 million |
|
Market Size in 2031 |
US$ 84,250.9 million |
|
By Drug Class |
|
|
By Disease Type |
|
|
Distribution Channel |
|
Download Free Sample Report
North America Anti diabetic Biosimilars Market size was valued at US$ 9,690.2 million in 2024 and is expected to reach US$ 84,250.9 million by 2031, growing at a significant CAGR of 36.2% from 2025-2031.
The market key players are Boehringer Ingelheim GmbH Eli Lilly & Co. , Sanofi-aventis U.S. LLC, Samsung Bioepis (Samsung BioLogics) , Mylan N.V. , Wockhardt
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
| 1.Executive Summary |
| 2.North America Anti diabetic Biosimilars Market Introduction |
| 2.1.North America Anti diabetic Biosimilars Market - Taxonomy |
| 2.2.North America Anti diabetic Biosimilars Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Disease Type |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.North America Anti diabetic Biosimilars Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.North America Anti diabetic Biosimilars Market Analysis, 2020-2024 and Forecast 2025-2031 |
| 4.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.North America Anti diabetic Biosimilars Market By Drug Class, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 5.1. Insulin |
| 5.1.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Biguanides |
| 5.2.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Sulfonyl Ureas |
| 5.3.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Thiazolidinediones |
| 5.4.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors |
| 5.5.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. glucosidase Inhibitos |
| 5.6.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. GLP-1 Agonists |
| 5.7.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Others |
| 5.8.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 6.North America Anti diabetic Biosimilars Market By Disease Type, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 6.1. Type-I Diabetes |
| 6.1.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Type-II Diabetes |
| 6.2.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.North America Anti diabetic Biosimilars Market By Distribution Channel , 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacies |
| 7.3.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.North America Anti diabetic Biosimilars Market By Region, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2020-2024 and Forecast 2025-2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 9.North America Anti diabetic Biosimilars Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 9.1. Drug Class Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Insulin |
| 9.1.2.Biguanides |
| 9.1.3.Sulfonyl Ureas |
| 9.1.4.Thiazolidinediones |
| 9.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors |
| 9.1.6.glucosidase Inhibitos |
| 9.1.7.GLP-1 Agonists |
| 9.1.8.Others |
| 9.2. Disease Type Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Type-I Diabetes |
| 9.2.2.Type-II Diabetes |
| 9.3. Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Retail Pharmacies |
| 9.3.3.Online Pharmacies |
| 9.4. Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10 Disease Type Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Type-I Diabetes |
| 10.2.2.Type-II Diabetes |
| 10.1. Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Retail Pharmacies |
| 10.3.3.Online Pharmacies |
| 10.2. Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11. Disease Type Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Type-I Diabetes |
| 11.2.2.Type-II Diabetes |
| 11.1 Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Retail Pharmacies |
| 11.3.3.Online Pharmacies |
| 11.2. Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12. Disease Type Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Type-I Diabetes |
| 12.2.2.Type-II Diabetes |
| 12.1. Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Retail Pharmacies |
| 12.3.3.Online Pharmacies |
| 12.2. Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1 Disease Type Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.2.Type-I Diabetes |
| 12.2.3.Type-II Diabetes |
| 13. Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacies |
| 13.3.2.Retail Pharmacies |
| 13.3.3.Online Pharmacies |
| 13.1. Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Boehringer Ingelheim GmbH |
| 14.2.2.Eli Lilly & Co. |
| 14.2.3.Sanofi-aventis U.S. LLC |
| 14.2.4.Samsung Bioepis (Samsung BioLogics) |
| 14.2.5.Mylan N.V. |
| 14.2.6.Wockhardt |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
